TSHATaysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. (TSHA) is a clinical-stage biotechnology company focused on developing AAV-based gene therapies for severe monogenic diseases of the central nervous system. The next catalyst is Oct 15, 2026 — Taysha Gene Therapies announces public offering pricing, which will test the market’s appetite for the company’s equity and its ability to secure capital amid ongoing financial pressure.
- TSHA has reported $1.99M in revenue for the 10-Q period ending June 30, 2026, but continues to operate at a steep net loss of -$148.66M.
- Free cash flow remains negative at -$231.67M over the last 12 months, with a debt-to-equity ratio of 0.15x.
- The company’s net margin is a brutal -7485.6% as it burns through cash to advance its pipeline.
The Read
TSHA's stock showed muted reaction to in-line earnings and cash runway confirmations but declined sharply—up to about 26%—when higher operating expenses and wider net losses overshadowed clinical progress updates, then rebounded about 14% on sustained confidence from positive preclinical data despite continued in-line EPS.
The schedule
- Sun4Oct
End-of-Year Regulatory & Tri
- Thu8Oct
Taysha Gene Therapies stock tumbles on public offering pricing
- Thu15Oct
The public offering pricing will test the market's reaction to the company's capital raise and its ability to secure funding at a favorable valuation. This event will also provide insight into investor confidence in the company's long-term growth prospects.
- Fri16Oct
The release of new ‘Anot’ data will test the market's response to updated clinical results, which could influence investor sentiment and the stock's short-term direction.
- Wed4Nov
The earnings release will test the company's ability to deliver positive guidance and revenue momentum, following a recent offering that caused a bearish reaction. The focus will be on the mix of revenue streams and cash flow generation.
- Thu24Dec
The conference and regulatory update will test the market's reaction to new information on the company's clinical progress and regulatory status, which could influence investor sentiment and the stock's short-term direction.
- Mon11Jan
The FDA's grant of Breakthrough Therapeutic Designation will test the market's reaction to the company's progress in its regulatory pathway, which could influence investor sentiment and the stock's short-term direction.
- Tue9Feb
This earnings release will test the company's ability to maintain revenue momentum and provide clarity on its cash runway. The market will be looking for signs of progress in clinical trials and regulatory filings.
- Wed5May
The Q1 2027 earnings release will test the company's ability to deliver on its long-term growth strategy, particularly in terms of clinical trial progress and regulatory milestones. The market will be looking for signs of positive data and increased investor confidence.
- Wed4Aug
The Q2 2027 earnings release will test the company's ability to maintain its growth trajectory and provide clarity on its long-term strategy. The market will be looking for signs of progress in clinical trials and regulatory filings.
- Wed3Nov
Past
- Thu1Oct
Actual outcome: Bear
Taysha Gene Therapies' stock fell 24.9% following the event, reaching below the bear floor of $4.20. The decline was driven by disappointing clinical trial results and a downward revision in revenue guidance, which signaled heightened regulatory and operational risks. These developments overshadowed any potential positive catalysts, leading to a sharp sell-off.
Stock price reaction to news event, likely tied to regulatory or clinical updates.
- Wed5Aug
Actual outcome: Bear · $5.69 at outcome
TSHA missed earnings expectations, with an EPS of -0.43 vs. -0.43, but the stock fell 12.1% as cash burn concerns intensified. The news highlighted deepening financial pressure, leading to a bearish reaction. The price dropped below the bear floor, reflecting investor concerns over the company's financial health and path to commercialization.
This earnings report will test the company's ability to manage cash burn and deliver on clinical progress, especially with the recent FDA Breakthrough Therapy designation. The outcome will be critical for assessing the company's path to commercialization and investor confidence.
- Fri5Jun
Actual outcome: Mixed · $5.70 at outcome
Taysha's stock trended higher after it was revealed that the company secured an accelerated FDA pathway for its lead gene therapy, TSHA-102, allowing it to skip Phase 3 trials for Rett syndrome. This shortened development timeline and promising early safety data drove investor optimism, pushing shares steadily upward in the weeks following the regulatory update.
Critical regulatory interaction clarifying manufacturing standards and trial endpoints for TSHA-102.
- Wed6May
Actual outcome: Bull · $6.84 at outcome
Taysha Gene Therapies reported Q1 2026 earnings with an EPS of -$0.12, exactly meeting analyst estimates, alongside a corporate update affirming its clinical pipeline progress. Sustained investor confidence, bolstered by recent positive preclinical data for TSHA-102 in Rett Syndrome, kept the stock trading at elevated levels. Despite a minor 2.3% dip following the release, shares closed at $6.82, successfully exceeding the $6.40 bull target.
First quarter results detailing operating cash flows and affirming pipeline runway.
- Thu19Mar
Actual outcome: Bear · $4.54 at outcome
Taysha Gene Therapies reported in-line EPS of -$0.08 but disclosed higher operating expenses and a wider net loss for the full year. Although the company highlighted clinical progress for its TSHA-102 Rett syndrome program and confirmed it is on track to complete dosing in Q2 2026, concerns over the increased cash burn weighed on investor sentiment, driving the stock below the bear floor.
Taysha reports Q2 2026 financials, with intense market focus on the trajectory of its $40.9M quarterly cash burn against its $276M reserve.
- Thu19Mar
Actual outcome: Mixed · $4.58 at outcome
TSHA reported Q4 2025 EPS of -$0.08, exactly meeting consensus estimates. Although the stock's initial reaction was flat, shares subsequently surged well past the bull target to $6.53 as the in-line earnings and full-year 2026 guidance provided the stability needed for the market to confidently price in the company's long-term pipeline potential.